SOPHiA GENETICS SA

SOPHiA GENETICS SA

6.80
EUR
-0.05
(-0.73%)
-0.96EPS
638.15MMarket Cap
Mar 09Next Earn

Total Valuation

EUR

As of September 30, 2026, SOPHiA GENETICS SA carries a market capitalization of 638.15M, placing it among publicly traded companies globally. Its enterprise value stands at 609.38M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap638.15M
Enterprise Value609.38M

Important Dates

SOPHiA GENETICS SA's next confirmed earnings release is scheduled for March 9, 2027.

Earnings Date3/9/2027

Share Statistics

As of September 30, 2026, SOPHiA GENETICS SA has 85.66M shares outstanding.

Shares Outstanding85.66M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 6.94, and the price-to-book ratio stands at 10.57.

PS Ratio6.94
PB Ratio10.57
P/TBV Ratio22.20
P/FCF Ratio-15.24
P/OCF Ratio-15.61

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 7.59 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 609.38M versus a market cap of 638.15M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales7.59

Financial Position

As of September 30, 2026, SOPHiA GENETICS SA maintains a current ratio of 2.29, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 89.20, indicating elevated leverage, while an interest coverage ratio of -9.54 demonstrates limited ability to service its debt obligations.

Current Ratio2.29
Quick Ratio2.01
Debt / Equity89.20
Debt / EBITDA-0.97
Interest Coverage-9.54

Financial Efficiency

EUR

Over the twelve months ended September 30, 2026, SOPHiA GENETICS SA posted a negative return on equity (ROE) of -125.67, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -46.60, reflecting losses generated across the asset base. The company generates approximately 193,408.66 in revenue per employee across its workforce of 415.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.41 indicates how many times SOPHiA GENETICS SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-125.67
Return on Assets (ROA)-46.60
Revenue Per Employee193,408.66
Employee Count415.00
Inventory Turnover4.41

Taxes

EUR

Over the twelve months ended September 30, 2026, SOPHiA GENETICS SA recorded 220,575.00 in income tax expense. The company reported a pretax loss of -71.36M and -71.58M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax220,575.00

Stock Price Statistics

EUR

As of the close on November 17, 2026, SOPHiA GENETICS SA's stock has gained approximately 88.89% over the past 52 weeks. The 50-day moving average sits at 6.76, while the 200-day moving average is 5.30.

52-Week Price Change88.89%
50-Day Moving Average6.76
200-Day Moving Average5.30

Income Statement

EUR

Over the twelve months ended September 30, 2026, SOPHiA GENETICS SA generated 80.26M in revenue and converted that into -71.58M in net income, yielding earnings per share of -0.96. EBITDA reached -55.37M, while operating income came in at -65.00M.

Revenue80.26M
Gross Profit53.32M
Operating Income-65.00M
Pretax Income-71.36M
Net Income-71.58M
EBITDA-55.37M
EBIT-65.00M
Earnings Per Share (EPS)-0.96

Balance Sheet

EUR

As of September 30, 2026, SOPHiA GENETICS SA holds 82.63M in cash and equivalents against 53.86M in total debt, resulting in a net debt position of -40.15M. Total book value stands at 60.37M, with working capital of 62.39M providing operational flexibility.

Cash & Cash Equivalents82.63M
Total Debt53.86M
Net Debt-40.15M
Equity (Book Value)60.37M
Book Value Per Share0.70
Working Capital62.39M

Cash Flow

EUR

SOPHiA GENETICS SA produced -35.67M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -860,242.50 in capital expenditures, free cash flow totaled -36.53M - equivalent to -0.49 per share.

Operating Cash Flow-35.67M
Capital Expenditures-860,242.50
Free Cash Flow-36.53M
FCF Per Share-0.49

Margins

Over the twelve months ended September 30, 2026, SOPHiA GENETICS SA posted a gross margin of 66.43, reflecting its pricing power and cost economics. The operating margin of -80.99 and net profit margin of -89.18 provide insight into operational efficiency.

Gross Margin66.43
Operating Margin-80.99
Pretax Margin-88.91
Profit Margin-89.18
EBITDA Margin-68.98

Dividends & Yields

Over the twelve months ended September 30, 2026, SOPHiA GENETICS SA paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -6.56: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.93, meaning SOPHiA GENETICS SA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-8.93
FCF Yield-6.56

Scores

As of September 30, 2026, SOPHiA GENETICS SA has an Altman Z-Score of -2.19, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-2.19